Ignite Creation Date:
2024-05-06 @ 1:23 PM
Last Modification Date:
2024-10-26 @ 1:13 PM
Study NCT ID:
NCT04009057
Status:
COMPLETED
Last Update Posted:
2022-05-03
First Post:
2019-07-02
Brief Title:
Effectiveness Safety Adherence and Health-related Quality of Life in HIV-1 Infected Adults Receiving Bictegravir EmtricitabineTenofovir Alafenamide BFTAF
Sponsor:
Gilead Sciences
Organization:
Gilead Sciences
Study Overview
Official Title:
Multi-center Israeli Non-interventional Cohort Study of the Effectiveness Safety Adherence and Health-related Quality of Life in HIV-1 Infected Adult Patients Receiving Bictegravir EmtricitabineTenofovir Alafenamide BFTAF
Status:
COMPLETED
Status Verified Date:
2022-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BIC-STaR
Brief Summary:
The primary objective of this study is to evaluate HIV-1 RNA suppression defined as HIV-1 RNA 50 copiesmL at 12 months after initiating or switching to bictegravir emtricitabinetenofovir alafenamide BFTAF
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None